Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9103848 | 1.00 | MAPT (0.43) | MAPTRAB9AL3MBTL1DRD2DRD4 | |
| SCHEMBL9105476 | 0.86 | ALDH1A1 (0.37) | HPGD | |
| SCHEMBL9105466 | 0.86 | ALDH1A1 (0.37) | HPGD | |
| SCHEMBL9102325 | 0.86 | MAPT (0.46) | MAPTRAB9AL3MBTL1HPGDTDP1 | |
| SCHEMBL9103007 | 0.86 | CHRNA1 (0.48) | MAPTRAB9AL3MBTL1HPGD | |
| SCHEMBL9103021 | 0.86 | CHRNA1 (0.48) | MAPTRAB9AL3MBTL1HPGD | |
| SCHEMBL9102341 | 0.86 | MAPT (0.46) | MAPTRAB9AL3MBTL1HPGDTDP1 | |
| SCHEMBL9099470 | 0.85 | CHRNA1 (0.50) | MAPTRAB9AHPGDTDP1 | |
| SCHEMBL9276080 | 0.84 | OPRK1 (0.46) | — | |
| SCHEMBL9105132 | 0.84 | DRD4 (0.39) | L3MBTL1DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130143858-A1 | COMPOUNDS AND THEIR USE AS IKACH BLOCKERS | ASTRAZENECA AB (SE) | 2013-06-06 | — | — | US | disclosed |
| US-8361998-B2 | Compounds and their use as IKACh blockers | ASTRAZENECA AB | 2013-01-29 | — | — | US | disclosed |
| WO-2012074469-A1 | NEW IKACH BLOCKERS | ASTRAZENECA AB (SE) | 2012-06-07 | — | — | WO | disclosed |
| US-20120142659-A1 | COMPOUNDS AND THEIR USE AS IKACH BLOCKERS | ASTRAZENECA AB (SE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143858-A1 | COMPOUNDS AND THEIR USE AS IKACH BLOCKERS | KCNH2, KCNJ2, KCNH3 | MAPT 4249/4885RAB9A 1554/4885L3MBTL1 1425/4885 |
| US-20120142659-A1 | COMPOUNDS AND THEIR USE AS IKACH BLOCKERS | KCNH2, KCNJ2, KCNH3 | MAPT 4249/4885RAB9A 1554/4885L3MBTL1 1425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.